Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.biomaterials.2008.02.020
DC FieldValue
dc.titleTargeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles
dc.contributor.authorPan, J.
dc.contributor.authorFeng, S.-S.
dc.date.accessioned2014-06-17T07:50:06Z
dc.date.available2014-06-17T07:50:06Z
dc.date.issued2008-06
dc.identifier.citationPan, J., Feng, S.-S. (2008-06). Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. Biomaterials 29 (17) : 2663-2672. ScholarBank@NUS Repository. https://doi.org/10.1016/j.biomaterials.2008.02.020
dc.identifier.issn01429612
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/64685
dc.description.abstractWe synthesized nanoparticles (NPs) of the blend of two-component copolymers for targeted chemotherapy with paclitaxel used as model drug. One component is poly(lactide)-d-α-tocopheryl polyethylene glycol succinate (PLA-TPGS), which is of desired hydrophobic-lipophilic balance, and another is TPGS-COOH, which facilitates the folate conjugation for targeting. The nanoparticles of the two-copolymer blend at various component ratio were prepared by the solvent extraction/evaporation single emulsion method and then decorated by folate, which were characterized by laser light scattering (LLS) for particles' size and size distribution, zeta potential analyzer for surface charge, and X-ray photoelectron spectroscopy (XPS) for surface chemistry. The drug encapsulation efficiency (EE) and in vitro drug release were measured by high performance liquid chromatography (HPLC). The targeting effect was investigated in vitro by cancer cell uptake of coumarin-6-loaded NPs and further confirmed by cytotoxicity of cancer cells treated with the drug formulated in the NPs. We showed that the NP formulation has great advantages vs the pristine drug in achieving better therapeutic effect, which increased 8.68% for MCF-7 breast cancer cells, and that the folate-decoration can significantly promote targeted delivery of the drug into the corresponding cancer cells and thus enhance its therapeutic effect, which increased 24.4% for the NP formulation of 16.7% TPGS-COOH component and 31.1% for the NP formulation of 33.3% TPGS-COOH component after 24 h treatment at the same 25 μg/ml paclitaxel concentration. The experiments on C6 glioma cells further confirmed these advantages. © 2008.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.biomaterials.2008.02.020
dc.sourceScopus
dc.subjectBiodegradable polymers
dc.subjectBreast cancer
dc.subjectCancer nanotechnology
dc.subjectNanobiotechnology
dc.subjectNanomedicine
dc.typeArticle
dc.contributor.departmentCHEMICAL & BIOMOLECULAR ENGINEERING
dc.description.doi10.1016/j.biomaterials.2008.02.020
dc.description.sourcetitleBiomaterials
dc.description.volume29
dc.description.issue17
dc.description.page2663-2672
dc.description.codenBIMAD
dc.identifier.isiut000256314400012
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.